Abstracts tagged "spondyloarthritis"

Abstract Number: 1899 • ACR Convergence 2020
Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Zhixiu Li¹, Mohammad Khan², Sjef van der Linden³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶, Matthew Brown⁷ and Muhammad Khan⁸, ¹Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ²Kent State University, Kent, OH, ³Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁸Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: To investigate life expectancy of a Swiss cohort of patients with ankylosing spondylitis (AS) versus general population during 35 years of longitudinal follow up,…
Abstract Number: 2030 • ACR Convergence 2020
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy¹, Valeria Rios Rodriguez², Murat Torgutalp², Ani Dilbaryan², Maryna Verba², Mikhail Protopopov², Fabian Proft², Judith Rademacher², Hildrun Haibel², Martin Rudwaleit³ and Joachim Sieper², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: There are conflicting data on the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on radiographic spinal progression in axial spondyloarthritis (axSpA). One randomized controlled trial…
Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Soumya Chakravarty², Robert McLean³, Taylor Blachley³, Toana Kawashima⁴, Iris Lin⁵, Jonathan Uy⁶, Arthur Kavanaugh⁷ and Alexis Ogdie⁸, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Scientific Affairs, LLC, Horsham, ⁷UC San Diego Health System, San Diego, CA, ⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
Abstract Number: 0879 • ACR Convergence 2020
Application of Treat-to-Target in Axial Spondyloarthritis in Daily Practice
Esther Beckers¹, Annelies Boonen¹, Casper Webers¹, Peter Ten Klooster², Harald Vonkeman², Monique Efde³ and Astrid van Tubergen⁴, ¹Maastricht University Medical Center, Maastricht, Netherlands, ²University of Twente, Enschede, Netherlands, ³VieCuri Medical Center, Venlo, Netherlands, ⁴Maastricht University Medical Center, Maastricht
Background/Purpose: Treat-to-target (T2T) management strategies in inflammatory rheumatic diseases aim to prevent damage and improve overall functioning and health by treating patients towards a predefined…
Abstract Number: 1306 • ACR Convergence 2020
High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred with Anterior Uveitis and Chronic Back Pain
Rianne van Bentum¹, Frank Verbraak², Sanne Wolf³, Maarten Boers⁴, Stevie Tan⁵ and Irene van der Horst-Bruinsma¹, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³Amsterdam University Medical Center location VUmc, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To reduce the diagnostic delay in axial spondyloarthritis (axSpA), Rheumatology and Ophthalmology guidelines recommend to refer patients with acute anterior uveitis (AAU) and chronic…
Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Filip Van den Bosch¹, Peter Nash², James Cheng-Chung Wei³, Francisco Blanco⁴, Vassilis Tsekouras⁵, Chuanbo Zang⁶, Daniela Graham⁷, Edmund Arthur⁸, Pamela Selema⁶, Bonnie Vlahos⁶ and Atul Deodhar⁹, ¹Ghent University Hospital, Ghent, Belgium, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁵Pfizer, Nicosia, Cyprus, ⁶Pfizer, Collegeville, PA, ⁷Pfizer, Groton, PA, ⁸Pfizer, Peapack, NJ, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…
Abstract Number: 1552 • ACR Convergence 2020
Ultrasound Doppler Enthesitis Shows Sensitivity to Change After Biological Therapy in Spondyloarthritis and Psoriatic Arthritis Patients
Juan Molina Collada¹, Cristina Macía-Villa², Chamaida Plasencia³, Jose Maria Alvaro-Gracia⁴ and Eugenio De Miguel⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital Universitario Severo Ochoa, Madrid, Spain, ³Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ⁴CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The assessment of activity in spondyloarthritis (SpA) and psoriatic arthritis (PsA) involves several domains, including enthesitis. Clinical enthesitis has shown low sensitivity, specificity and…
Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Sofia Exarchou⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…
Abstract Number: 1900 • ACR Convergence 2020
The Clinical and the Functional Impact of Central Sensitization on Patients with Axial Spondyloarthritis
Feyza Nur Yücel¹ and Mehmet Tuncay Duruöz², ¹Marmara University School of Medicine PMR Department, Istanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey
Background/Purpose: To evaluate the impact of central sensitization (CS) on axial spondyloarthritis (AxSpA) patients’ clinical and functional situation and quality of life.Methods: Subjects with axSpA…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 0361 • ACR Convergence 2020
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Victoria Navarro-Compán¹, Jose Maldonado-Cocco², Proton Rahman³, Andris Kronbergs⁴, David Sandoval⁴, So Young Park⁴, Theresa Hunter⁴ and Marina Magrey⁵, ¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ²University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Eli Lilly and Company, Indianapolis, ⁵Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In this analysis, we evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27…
Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Georg Schett¹, Filip Van den Bosch², Xenofon Baraliakos³, David Sandoval⁴, Vladimir Geneus⁴, Rebecca Bolce⁴, Soyi Liu-Leage⁵, Andris Kronbergs⁴ and Philip Mease⁶, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Ghent University Hospital, Ghent, Belgium, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁴Eli Lilly and Company, Indianapolis, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…
Abstract Number: 1307 • ACR Convergence 2020
Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial Spondyloarthritis with Deep Learning
Yun Ju Huang¹, Chang-Fu Kuo², Yu Huei Huang³, Yih Shiou Hwang⁴ and Chihung Lin⁵, ¹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan (Republic of China), ²Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), ³Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁴Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), ⁵Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China)
Background/Purpose: Fundoscopy is essential to identify the retinopathy of patients with autoimmune diseases. However, the classification of different autoimmune diseases is difficult by human eyes…
Abstract Number: 1347 • ACR Convergence 2020
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
Walter Maksymowych¹, Thomas Kumke², Simone Auteri³, Bengt Hoepken², Lars Bauer² and Martin Rudwaleit⁴, ¹University of Alberta, Edmonton, AB, Canada, ²UCB Pharma, Monheim am Rhein, Germany, ³UCB Pharma, Milan, Italy, ⁴Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Identification of predictive clinical factors of long-term treatment response in non-radiographic axial spondyloarthritis (nr-axSpA) may contribute to improved management of patients with this chronic…
Abstract Number: 1561 • ACR Convergence 2020
Findings Compatible with Axial Spondyloarthritis in Radiologist Reports
Rouhin Sen¹, Emmeline Kim², Evan Manning³, Eric Anderson⁴, Kyle Maier⁵, Elizabeth Cheng⁶ and Liron Caplan⁶, ¹University of Colorado - Division of Rheumatology, Denver, CO, ²University of Colorado School of Medicine, Denver, ³University of Colorado - Department of Medicine, Denver, ⁴Washington University - Division of Rheumatology, St. Louis, ⁵United States Air Force, San Antonio, TX, ⁶Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO
Background/Purpose: The sacroiliac joint (SIJ) has a distinct anatomical shape that can pose challenges to standard planar imaging techniques making the detection of subtle changes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].